"I feel so strongly that I can't be the one asking all the personal questions of, specifically, the Housewives
According to the FDA prescribing information, injection site reactions occur in approximately 1.7-5.2% of patients receiving tirzepatide, depending on the dose
Some patients may discuss switching from semaglutide to tirzepatide if progress has slowed, side effects are difficult to manage, appetite control is not adequate or the provider believes another option may better fit the patients metabolic needs
CMED approval is a distinct process with its own timeline, which has not been made public
Peters, Lausanne (Oncologie)
Genetics, baseline metabolism, and individual receptor sensitivity influence timing